Patritumab deruxtecan induces immunogenic cell death

Patritumab deruxtecan induces immunogenic cell death

Antibody-drug conjugates (ADCs) enable targeted delivery of cytotoxic payload to cancer cells. Here, we characterized the mode of action of the ADC patritumab deruxtecan, which is a monoclonal antibody specific for Erb-B2 Receptor Tyrosine Kinase 3 (ERBB3, best known as HER3) coupled to the topoisom...

Full description

Saved in:
Bibliographic Details
Main Authors: Sabrina Forveille, Liwei Zhao, Allan Sauvat, Giulia Cerrato, Marion Leduc, Flora Doffe, Yuhong Pan, Peng Liu, Guido Kroemer, Oliver Kepp
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:OncoImmunology
Subjects:
Antibody drug conjugate
anticancer immunity
cancer
immunotherapy
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2025.2514050
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2025.2514050

Similar Items